Study Shows Thalidomide Heals Mouth Lesions In HIV Patients

May 22, 1997

By DAVID WILLIAMSON
UNC-CH News Services

CHAPEL HILL -- Thalidomide, the notorious drug that caused severe malformations in thousands of newborn infants more than a generation ago, safely and effectively heals mouth ulcers among people infected with the virus that causes AIDS, a new study concludes.

The study, published in Thursday's (May 22) New England Journal of Medicine, involved treating 29 HIV-positive patients complaining of painful mouth sores with thalidomide. Twenty-eight other patients received an inactive compound, or placebo.

Within four weeks, ulcers in 16 of 29 people who received the drug had healed completely. Only two of the 28 people receiving placebo showed ulcer healing. Thalidomide treatment also reduced pain the ulcers caused and boosted patients' ability to eat.

Ninety percent of treatment group volunteers showed at least partial healing, and some healed completely within one week of receiving 200 milligrams of the drug daily.

Authors of the journal report include Drs. Jeffrey M. Jacobson of the Bronx Veterans Affairs Medical Center and David A. Wohl of the University of North Carolina at Chapel Hill School of Medicine. Scientists and patients at Johns Hopkins and Harvard universities, the universities of California at San Francisco and Los Angeles and other institutions also participated.

"From this study we learned that thalidomide, probably the most notorious drug ever marketed in modern times, is clearly beneficial to people with this devastating problem," said Wohl, research associate in infectious diseases at UNC-CH. "Several of our patients were about to have tubes put in their stomachs because they were no longer able to eat. We used thalidomide successfully with these patients, and it helped them greatly by allowing them to eat on their own and to leave the hospital."

Wohl and his UNC-CH colleagues enrolled 13 of 57 patients treated nationwide, more than any other institution.

Seven patients said the thalidomide caused sleepiness, and seven others experienced rashes, he said. Six people in the treatment group dropped out of the study because of side effects, but most could be managed well by reducing the dose. No significant differences were found between the treated and non-treated groups in serious side effects, which were minimal.

Dr. Charles van der Horst, director of the AIDS Clinical Trials Unit at UNC-CH, collaborated with Wohl.

Since the long-term side effects of thalidomide in people with HIV infection are not yet known, Wohl and his colleagues urged caution in using the drug for more than the two to four weeks needed to heal the ulcers. Why the ulcers occur is not known, but possible causes include viruses, immune system changes, hormones and stress.

Clinicians counseled the seven women in the study about the drug's power to cause birth defects and made them promise to use two to three birth control methods simultaneously if they engaged in sex. Men also received counseling about the hazards.

The AIDS Clinical Trials Group, the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources supported the research.

Thalidomide, a sedative, originally was marketed as a safe alternative to barbiturates for people who were anxious or could not sleep.

- 30 -

Note: Wohl and van der Horst can be reached at (919) 966-2536. Wohl's pager number is 216-0629.
Contact: David Williamson

University of North Carolina at Chapel Hill

Related Aids Articles from Brightsurf:

Developing a new vaccination strategy against AIDS
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys.

HIV-AIDS: Following your gut
Researchers find a way to reduce replication of the AIDS virus in the gastrointestinal tract.

A path toward ending AIDS in the US by 2025
Using prevention surveillance data to model rates of HIV incidence, prevalence and mortality, investigators at Brigham and Women's Hospital and Johns Hopkins Bloomberg School of Public Health set targets, specifically a decrease in new infections to 21,000 by 2020 and to 12,000 by 2025, that would mark a transition toward ending the HIV/AIDS epidemic.

What does it take for an AIDS virus to infect a person?
Researchers examined the characteristics of HIV-1 strains that were successful in traversing the genital mucosa that forms a boundary to entry by viruses and bacteria.

How AIDS conquered North America
A new technique that allowed researchers to analyze genetic material from serum samples of HIV patients taken before AIDS was known provides a glimpse of unprecedented detail into the beginnings of the AIDS epidemic in North America.

New research could help build better hearing aids
Scientists at Binghamton University, State University of New York want to improve sensor technology critical to billions of devices made every year.

NY State Department of Health AIDS Institute funds HIV/AIDS prevention in high-risk youth
NewYork-Presbyterian's Comprehensive Health Program and Project STAY, an initiative of the Harlem Heath Promotion Center (HHPC) at Columbia University's Mailman School of Public Health has received two grants totaling more than $3.75 million from the New York State Department of Health AIDS Institute for their continued efforts to prevent HIV/AIDS in at-risk youth.

A new way to nip AIDS in the bud
When new HIV particles bud from an infected cell, the enzyme protease activates to help the viruses infect more cells.

AIDS research prize for Warwick academic
A researcher at the University of Warwick has received international recognition for his contribution to AIDS research.

Insects inspire next generation of hearing aids
An insect-inspired microphone that can tackle the problem of locating sounds and eliminate background noise is set to revolutionize modern-day hearing aid systems.

Read More: Aids News and Aids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.